<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005975</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-A-301</org_study_id>
    <nct_id>NCT05005975</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of oral dersimelagon.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]).</measure>
    <time_frame>up to a maximum 24 months</time_frame>
    <description>Vital signs (blood pressure, respiratory rate, pulse rate, and body temperature), Clinical laboratory examinations (hematology, coagulation, biochemistry, urinalysis, and others), 12-lead electrocardiogram (ECG) parameters (Mean Heart Rate, PR Interval, QRS Duration, QT interval, QTcB and QTcF) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal Physical examination data</measure>
    <time_frame>up to a maximum 24 months</time_frame>
    <description>Physical examination consists of assessment of abdominal, respiratory, cardiovascular, general appearance, and others.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Nevi appearance</measure>
    <time_frame>up to a maximum 24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>EPP</condition>
  <condition>XLP</condition>
  <arm_group>
    <arm_group_label>Dersimelagon 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>MT-7117</description>
    <arm_group_label>Dersimelagon 100mg</arm_group_label>
    <other_name>Dersimelagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects provided written informed consent to participate. For adolescent subjects,&#xD;
             both adolescent assent and parental consent will be provided.&#xD;
&#xD;
          -  2. Subjects who complete MT-7117-G01 (complete through Week 58 [Visit 12])&#xD;
&#xD;
          -  3. Subjects have a body weight of ≥30 kg.&#xD;
&#xD;
          -  4. Subjects are willing and able to travel to the study sites for all scheduled&#xD;
             visits.&#xD;
&#xD;
          -  5. In the Investigator's opinion, subject can understand the nature of the study and&#xD;
             any risks involved in participation, and is willing to cooperate and comply with the&#xD;
             protocol restrictions and requirements (including travel).&#xD;
&#xD;
          -  6. Female subjects who are non-lactating and have a negative urine pregnancy test at&#xD;
             baseline visit prior to receiving the first dose of study drug.&#xD;
&#xD;
          -  7. Female subjects of childbearing potential and male subjects with partner of&#xD;
             childbearing potential must agree to use 2 effective methods of contraception&#xD;
             including barrier method (especially for female subjects, one method must be highly&#xD;
             effective method)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will NOT be eligible for this study if ANY of the following criteria apply:&#xD;
&#xD;
          -  1. History or presence of photodermatoses other than EPP or XLP.&#xD;
&#xD;
          -  2. Presence of clinically significant hepatobiliary disease at Screening.&#xD;
&#xD;
          -  3. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin&#xD;
             &gt;1.5 × ULN at Screening.&#xD;
&#xD;
          -  4. Subjects with or having a history (in the last 2 years) of excessive alcohol intake&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
          -  5. History of melanoma.&#xD;
&#xD;
          -  6. Presence of melanoma and/or lesions suspicious for melanoma at Screening.&#xD;
&#xD;
          -  7. History of familial melanoma (defined as having 2 or more first-degree relatives,&#xD;
             such as parents, sibling and/or child).&#xD;
&#xD;
          -  8. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin&#xD;
             lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or&#xD;
             nevi cannot be resolved through biopsy or excision, the subject will be excluded from&#xD;
             the study.&#xD;
&#xD;
          -  9. History or presence of psychiatric disease judged to be clinically significant by&#xD;
             the Investigator and which may interfere with the study evaluation and/or safety of&#xD;
             the subjects.&#xD;
&#xD;
          -  10. Presence of clinically significant acute or chronic renal disease based upon the&#xD;
             subject's medical records including hemodialysis; an estimated glomerular filtration&#xD;
             rate (eGFR) &lt;60 mL/min/1.73m2 as calculated by the CKD-EPI creatinine equation (2009)&#xD;
             for adults and by the Schwartz creatinine equation for adolescents (2009). MDRD can be&#xD;
             used for adults per local recommendations.&#xD;
&#xD;
          -  11. Presence of any clinically significant disease or laboratory abnormality which, in&#xD;
             the opinion of the Investigator, can interfere with the study objectives and/or safety&#xD;
             of the subjects.&#xD;
&#xD;
          -  12. Female subjects who are pregnant, lactating, or intending to become pregnant&#xD;
             during the study.&#xD;
&#xD;
          -  13. Treatment with phototherapy or afamelanotide within 3 months before baseline&#xD;
             (Visit 2).&#xD;
&#xD;
          -  14. Treatment with cimetidine or antioxidant agents at doses which, in the opinion of&#xD;
             the Investigator, may affect study endpoints (including but not limited to&#xD;
             beta-carotene, cysteine, pyridoxine) within 4 weeks before baseline (Visit 2).&#xD;
&#xD;
          -  15. Chronic treatment with any scheduled analgesic agents including, but not limited&#xD;
             to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl,&#xD;
             or their combination with other unscheduled analgesics or non-steroidal&#xD;
             anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks&#xD;
             before baseline (Visit 2). Acute use of scheduled narcotics greater than 3 months&#xD;
             prior to baseline, over-the-counter medications (OTCs), such as non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or aspirin for analgesia, or prior temporary use of&#xD;
             scheduled agents within 3 months of baseline (Visit 2) are not excluded.&#xD;
&#xD;
          -  16. Treatment with any drugs or supplements which, in the opinion of the Investigator,&#xD;
             can interfere with the objectives of the study or safety of the subjects.&#xD;
&#xD;
          -  17. Previous treatment with any investigational agent other than dersimelagon within&#xD;
             12 weeks before Screening OR 5 half-lives of the investigational product (whichever is&#xD;
             longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, To prevent mis-communication,</last_name>
    <phone>please e-mail</phone>
    <email>information@mt-pharma-us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marvel Clinical Research, LLC</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco-CSF Porphyria Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicne, Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MetroBoston Clinical Partners, LLC</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135-3211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch (UTMB)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington-Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital (RMH)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westfaelische Wilhelms-Universitaet Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Northrhein Westalien</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.F.O. Hospital, Centro Porfirie e Malattie Rare</name>
      <address>
        <city>Rome</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evelina London Children's Hospital - Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

